Tested for in vivo antifilarial activity against Acanthocheilonema viteae macrofilariae infection in Mastomys coucha at 50 mg/kgx 5 days after ip administration, expressed as % reduction in parasite load
Tested for in vivo antifilarial activity against Acanthocheilonema viteae microfilariae infection in Mastomys coucha at 50 mg/kgx 5 days after ip administration, expressed as % reduction in parasite load
Tested for in vivo antifilarial activity against A. viteae microfilariae infection in Mastomys coucha at 50 mg/kgx 5 days after ip administration, expressed as % reduction in parasite load
Tested for in vivo antifilarial activity against Litomosoides carinii macrofilariae infection in Mastomys coucha at 30 mg/kgx 5 days after ip administration, expressed as % reduction in parasite load with 30% sterilization of female worms
Tested for in vivo antifilarial activity against Litomosoides carinii macrofilariae infection in Mastomys coucha at 350 mg/kgx 5 days after ip administration, expressed as % reduction in parasite load
Tested for in vivo antifilarial activity against Litomosoides carinii macrofilariae infection in Mastomys coucha at 6 mg/kgx 5 days after ip administration, expressed as % reduction in parasite load
Tested for in vivo antifilarial activity against Litomosoides carinii microfilariae infection in Mastomys coucha at 30 mg/kgx 5 days after ip administration, expressed as % reduction in parasite load with 30% sterilization of female worms
Tested for in vivo antifilarial activity against Litomosoides carinii microfilariae infection in Mastomys coucha at 350 mg/kgx 5 days after ip administration, expressed as % reduction in parasite load
Tested for in vivo antifilarial activity against Litomosoides carinii microfilariae infection in Mastomys coucha at 6 mg/kgx 5 days after ip administration, expressed as % reduction in parasite load
Toxicity in Mastomys coucha infected with third stage infective larvae (L3) form of Brugia malayi assessed as normal behaviour at at 100 mg/kg, sc administered for 5 days measured on day 91 post-initiation of drug treatment